BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15684051)

  • 21. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
    Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
    Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex and strain-based inflammatory response to repeated tobacco smoke exposure in spontaneously hypertensive and Wistar Kyoto rats.
    Shen YH; Pham AK; Davis B; Smiley-Jewell S; Wang L; Kodavanti UP; Takeuchi M; Tancredi DJ; Pinkerton KE
    Inhal Toxicol; 2016 Dec; 28(14):677-685. PubMed ID: 27829308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
    Koeners MP; Wesseling S; Ulu A; Sepúlveda RL; Morisseau C; Braam B; Hammock BD; Joles JA
    Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E691-8. PubMed ID: 21266668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
    Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
    Dorrance AM; Rupp N; Pollock DM; Newman JW; Hammock BD; Imig JD
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):842-8. PubMed ID: 16306811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
    Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
    Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
    Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
    J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
    Fang X
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions.
    Ingraham RH; Gless RD; Lo HY
    Curr Med Chem; 2011; 18(4):587-603. PubMed ID: 21143109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.
    Das Mahapatra A; Choubey R; Datta B
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33255197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble epoxide hydrolase inhibitor can protect the femoral head against tobacco smoke exposure-induced osteonecrosis in spontaneously hypertensive rats.
    Xu J; Qiu X; Yu G; Ly M; Yang J; Silva RM; Zhang X; Yu M; Wang Y; Hammock B; Pinkerton KE; Zhao D
    Toxicology; 2022 Jan; 465():153045. PubMed ID: 34801612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice.
    Shen N; Wang J; Zhao M; Pei F; He B
    Inhal Toxicol; 2011 Mar; 23(4):212-8. PubMed ID: 21456954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble epoxide hydrolase in rat inflammatory cells is indistinguishable from soluble epoxide hydrolase in rat liver.
    Draper AJ; Hammock BD
    Toxicol Sci; 1999 Jul; 50(1):30-5. PubMed ID: 10445750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.
    Napimoga MH; Rocha EP; Trindade-da-Silva CA; Demasi APD; Martinez EF; Macedo CG; Abdalla HB; Bettaieb A; Haj FG; Clemente-Napimoga JT; Inceoglu B; Hammock BD
    J Periodontal Res; 2018 Oct; 53(5):743-749. PubMed ID: 29851077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
    Liang Y; Jing Z; Deng H; Li Z; Zhuang Z; Wang S; Wang Y
    Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):70-5. PubMed ID: 25986738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epoxide hydrolase activities and epoxy fatty acids in the mosquito Culex quinquefasciatus.
    Xu J; Morisseau C; Yang J; Mamatha DM; Hammock BD
    Insect Biochem Mol Biol; 2015 Apr; 59():41-9. PubMed ID: 25686802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.
    Chen X; Chen X; Huang X; Qin C; Fang Y; Liu Y; Zhang G; Pan D; Wang W; Xie M
    Mol Neurobiol; 2016 Apr; 53(3):1565-1578. PubMed ID: 25663200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble Epoxide Hydrolase Pharmacological Inhibition Decreases Alveolar Bone Loss by Modulating Host Inflammatory Response, RANK-Related Signaling, Endoplasmic Reticulum Stress, and Apoptosis.
    Trindade-da-Silva CA; Bettaieb A; Napimoga MH; Lee KSS; Inceoglu B; Ueira-Vieira C; Bruun D; Goswami SK; Haj FG; Hammock BD
    J Pharmacol Exp Ther; 2017 Jun; 361(3):408-416. PubMed ID: 28356494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
    Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.